Treatment outcomes of radiotherapy for patients with stage I esophageal cancer: A single institute experience

Tomonari Sasaki, Katsumasa Nakamura, Yoshiyuki Shioyama, Yasushi Toh, Ken Okamura, Hiroki Ohura, Hideki Hirata, Hiroshi Honda

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

OBJECTIVES: To evaluate the effectiveness of radiotherapy for patients with stage I esophageal cancer. METHODS: From 1995 to 2005, 34 patients with superficial thoracic esophageal squamous cell carcinoma without lymph node metastasis were treated with radiotherapy at our institute. Patient characteristics were as follows: median age, 68 years; range, 47 to 84 years; male:female, 33:1; performance status, 0/1/2/3 = 23/9/1/1; T1a/T1b = 4/30. Median fraction and total doses of external irradiation given were 2.0 Gy and 60 Gy, respectively. Twenty-three patients had local irradiation to the primary lesion only; the remaining 11 patients received regional field irradiation, including one or 2 regional lymph node areas. Only one patient received adjuvant intracavitary radiotherapy after radiotherapy. Thirty of the patients received concurrent chemotherapy, most of the regimens of which included cisplatin and 5-fluorouracil. Adjuvant chemotherapy was performed in 5 patients. Fifteen patients (44%) had coexisting malignancies. The median follow-up was 38 months (range, 8-107 months). RESULTS: The 5-year overall, cause-specific, and local-progression-free survival rates were 50.4%, 91.2%, and 81.1%, respectively. Of the 34 patients, 6 had in-field local recurrence, and one had recurrence in the esophagus outside of the irradiated field. Two patients experienced regional lymph node metastasis outside of the irradiated field, and one had distant metastasis. Two patients received salvage surgery, and 4 patients received salvage intracavitary radiotherapy after local recurrence. A late toxicity greater than grade 2 was not observed in any patient. CONCLUSIONS: Radiotherapy is an effective treatment modality for patients with stage I esophageal cancer.

Original languageEnglish
Pages (from-to)514-519
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume30
Issue number5
DOIs
Publication statusPublished - Oct 1 2007

Fingerprint

Esophageal Neoplasms
Radiotherapy
Lymph Nodes
Neoplasm Metastasis
Recurrence
Adjuvant Radiotherapy
Adjuvant Chemotherapy
Fluorouracil
Cisplatin
Esophagus
Disease-Free Survival
Thorax

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Treatment outcomes of radiotherapy for patients with stage I esophageal cancer : A single institute experience. / Sasaki, Tomonari; Nakamura, Katsumasa; Shioyama, Yoshiyuki; Toh, Yasushi; Okamura, Ken; Ohura, Hiroki; Hirata, Hideki; Honda, Hiroshi.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 30, No. 5, 01.10.2007, p. 514-519.

Research output: Contribution to journalArticle

Sasaki, Tomonari ; Nakamura, Katsumasa ; Shioyama, Yoshiyuki ; Toh, Yasushi ; Okamura, Ken ; Ohura, Hiroki ; Hirata, Hideki ; Honda, Hiroshi. / Treatment outcomes of radiotherapy for patients with stage I esophageal cancer : A single institute experience. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2007 ; Vol. 30, No. 5. pp. 514-519.
@article{43664b05157246d594d46ba2e37e88b5,
title = "Treatment outcomes of radiotherapy for patients with stage I esophageal cancer: A single institute experience",
abstract = "OBJECTIVES: To evaluate the effectiveness of radiotherapy for patients with stage I esophageal cancer. METHODS: From 1995 to 2005, 34 patients with superficial thoracic esophageal squamous cell carcinoma without lymph node metastasis were treated with radiotherapy at our institute. Patient characteristics were as follows: median age, 68 years; range, 47 to 84 years; male:female, 33:1; performance status, 0/1/2/3 = 23/9/1/1; T1a/T1b = 4/30. Median fraction and total doses of external irradiation given were 2.0 Gy and 60 Gy, respectively. Twenty-three patients had local irradiation to the primary lesion only; the remaining 11 patients received regional field irradiation, including one or 2 regional lymph node areas. Only one patient received adjuvant intracavitary radiotherapy after radiotherapy. Thirty of the patients received concurrent chemotherapy, most of the regimens of which included cisplatin and 5-fluorouracil. Adjuvant chemotherapy was performed in 5 patients. Fifteen patients (44{\%}) had coexisting malignancies. The median follow-up was 38 months (range, 8-107 months). RESULTS: The 5-year overall, cause-specific, and local-progression-free survival rates were 50.4{\%}, 91.2{\%}, and 81.1{\%}, respectively. Of the 34 patients, 6 had in-field local recurrence, and one had recurrence in the esophagus outside of the irradiated field. Two patients experienced regional lymph node metastasis outside of the irradiated field, and one had distant metastasis. Two patients received salvage surgery, and 4 patients received salvage intracavitary radiotherapy after local recurrence. A late toxicity greater than grade 2 was not observed in any patient. CONCLUSIONS: Radiotherapy is an effective treatment modality for patients with stage I esophageal cancer.",
author = "Tomonari Sasaki and Katsumasa Nakamura and Yoshiyuki Shioyama and Yasushi Toh and Ken Okamura and Hiroki Ohura and Hideki Hirata and Hiroshi Honda",
year = "2007",
month = "10",
day = "1",
doi = "10.1097/COC.0b013e31805c1410",
language = "English",
volume = "30",
pages = "514--519",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Treatment outcomes of radiotherapy for patients with stage I esophageal cancer

T2 - A single institute experience

AU - Sasaki, Tomonari

AU - Nakamura, Katsumasa

AU - Shioyama, Yoshiyuki

AU - Toh, Yasushi

AU - Okamura, Ken

AU - Ohura, Hiroki

AU - Hirata, Hideki

AU - Honda, Hiroshi

PY - 2007/10/1

Y1 - 2007/10/1

N2 - OBJECTIVES: To evaluate the effectiveness of radiotherapy for patients with stage I esophageal cancer. METHODS: From 1995 to 2005, 34 patients with superficial thoracic esophageal squamous cell carcinoma without lymph node metastasis were treated with radiotherapy at our institute. Patient characteristics were as follows: median age, 68 years; range, 47 to 84 years; male:female, 33:1; performance status, 0/1/2/3 = 23/9/1/1; T1a/T1b = 4/30. Median fraction and total doses of external irradiation given were 2.0 Gy and 60 Gy, respectively. Twenty-three patients had local irradiation to the primary lesion only; the remaining 11 patients received regional field irradiation, including one or 2 regional lymph node areas. Only one patient received adjuvant intracavitary radiotherapy after radiotherapy. Thirty of the patients received concurrent chemotherapy, most of the regimens of which included cisplatin and 5-fluorouracil. Adjuvant chemotherapy was performed in 5 patients. Fifteen patients (44%) had coexisting malignancies. The median follow-up was 38 months (range, 8-107 months). RESULTS: The 5-year overall, cause-specific, and local-progression-free survival rates were 50.4%, 91.2%, and 81.1%, respectively. Of the 34 patients, 6 had in-field local recurrence, and one had recurrence in the esophagus outside of the irradiated field. Two patients experienced regional lymph node metastasis outside of the irradiated field, and one had distant metastasis. Two patients received salvage surgery, and 4 patients received salvage intracavitary radiotherapy after local recurrence. A late toxicity greater than grade 2 was not observed in any patient. CONCLUSIONS: Radiotherapy is an effective treatment modality for patients with stage I esophageal cancer.

AB - OBJECTIVES: To evaluate the effectiveness of radiotherapy for patients with stage I esophageal cancer. METHODS: From 1995 to 2005, 34 patients with superficial thoracic esophageal squamous cell carcinoma without lymph node metastasis were treated with radiotherapy at our institute. Patient characteristics were as follows: median age, 68 years; range, 47 to 84 years; male:female, 33:1; performance status, 0/1/2/3 = 23/9/1/1; T1a/T1b = 4/30. Median fraction and total doses of external irradiation given were 2.0 Gy and 60 Gy, respectively. Twenty-three patients had local irradiation to the primary lesion only; the remaining 11 patients received regional field irradiation, including one or 2 regional lymph node areas. Only one patient received adjuvant intracavitary radiotherapy after radiotherapy. Thirty of the patients received concurrent chemotherapy, most of the regimens of which included cisplatin and 5-fluorouracil. Adjuvant chemotherapy was performed in 5 patients. Fifteen patients (44%) had coexisting malignancies. The median follow-up was 38 months (range, 8-107 months). RESULTS: The 5-year overall, cause-specific, and local-progression-free survival rates were 50.4%, 91.2%, and 81.1%, respectively. Of the 34 patients, 6 had in-field local recurrence, and one had recurrence in the esophagus outside of the irradiated field. Two patients experienced regional lymph node metastasis outside of the irradiated field, and one had distant metastasis. Two patients received salvage surgery, and 4 patients received salvage intracavitary radiotherapy after local recurrence. A late toxicity greater than grade 2 was not observed in any patient. CONCLUSIONS: Radiotherapy is an effective treatment modality for patients with stage I esophageal cancer.

UR - http://www.scopus.com/inward/record.url?scp=35148847348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35148847348&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e31805c1410

DO - 10.1097/COC.0b013e31805c1410

M3 - Article

C2 - 17921713

AN - SCOPUS:35148847348

VL - 30

SP - 514

EP - 519

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -